Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo‐adjuvant treatment for Her2 positive breast cancer patients and impact of colony‐stimulating factor prophylaxis

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles